To Get Help Now
Click Here
 
Today's Date:

Lawsuit Filed In Ohio Over Actos Use and Bladder Cancer

AddThis Social Bookmark Button

An Ohio couple has  filed a lawsuit against Takeda Pharmaceuticals in U.S. District Court for the Northern District of Ohio, Eastern Division, alleging the type 2 diabetes medication caused bladder cancer.

The lawsuits states “[d]efendants concealed and continue to conceal their knowledge of Actos’ unreasonably dangerous risks from consumers, and the medical community. Specifically, Defendants failed to adequately inform consumers and the prescribing medical community about the risk of bladder cancer associated with more than twelve (12) months of Actos ingestion.”

The lawsuit also claims that “Prior to Actos being approved by the FDA, a two-year carcinogenicity study was

conducted on male and female rats. Drug-induced tumors were observed in male rats receiving doses of Actos that produced blood drug levels equivalent to those resulting from a clinical dose. In 2005, the results of the PROactive (PROspective PioglitAzone Clinical Trial In MacroVascular Events) three-year study were published. PROactive prospectively looked at the impact in total mortality and macrovascular morbidity using Actos.” The lawsuit continued, the study “demonstrated a higher percentage of bladder cancer cases in patients receiving Actos versus comparators.” A separate three-year liver study was also performed and showed “a higher percentage of bladder cancer cases in patients receiving Actos versus comparators.”

The lawsuits seeks damages, ascertainable economic losses, attorneys’ fees, reimbursement of cost of obtaining Actos, reimbursement for all past, present, and future health and medical care costs related to Actos.

breakinglawsuitnews.com disclaimer: This article: Lawsuit Filed In Ohio Over Actos Use and Bladder Cancer was posted on Tuesday, August 9th, 2011 at 7:21 pm at breakinglawsuitnews.com and is filed under Defective Drug Lawsuits.

« »

Leave a Reply

You must be logged in to post a comment.